Program
resmetirom
Also written as “Resmetirom”, “MGL-3196” and “VIA-3196”.
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Fatty Liver · Liver Diseases · Fibrosis · Liver Cirrhosis, led by 3 companies.
Drug pageResmetirom: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Madrigal Pharmaceuticalsits history only | 207 open or running | phase 4since Aug 25, 2026 | Jun 2, 2011 | Dec 2026phase 3 · NCT05500222 |
| Nabiqasim Industries (Pvt)its history only | 11 open or running | phase 4since Nov 18, 2025 | Nov 18, 2025 | none ahead |
| Sagimet Biosciences | 10 open or running | phase 1since Oct 8, 2025 | Oct 8, 2025 | none ahead |
Also a collaborator on its studies: Celerion.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sagimet Biosciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2018Named resmetiromINNProposed as its International Nonproprietary Name in WHO's List 119 · before, MGL-3196, VIA-3196
- Oct 8, 2025First study: phase 1 study in HealthyFirst studyNCT07216313 · 40 enrolled · United States
TargetBeta
“Thyroid hormone receptor beta-1 agonist”ChEMBL 37, by rule
Other programs on THRB
Studies
The one study Sagimet Biosciences leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07216313Healthy · United States | 1 | Completed | Oct 20, 2025 | 40 |
How it is read
Names in the registry
- “Resmetirom”, 9 entries
- “MGL-3196”, 8 entries
- “VIA-3196”, 2 entries
- “Rezdiffra”, 1 entry
- “MGL-3196 (resmetirom)”, 1 entry
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 5 studies
- Fatty Liver, 3 studies
- Liver Diseases, 1 study
- Fibrosis, 1 study
- Liver Cirrhosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.